logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
TVTX
Travere Therapeutics, Inc.
52.13
2 x 47.37
2 x 78.79
bid
ask
+
0.09
0.16%
2 @ 04:00 PM
52.13 +0.00 (0.00%)
Ytd36.42%
1y99.94%
51.63
day range
52.71
25.16
52 week range
67.52
Open52.07Prev Close52.04Low51.63High52.71Mkt Cap4.85B
Vol1.17MAvg Vol1.59MEPS-0.74P/EN/AForward P/E9.24
Beta1.14Short Ratio10.19Inst. Own115.19%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning10-2950-d Avg62.13200-d Avg45.401yr Est75.21

TVTX News

Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
businesswire.com
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephr

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that

Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm
prnewswire.com
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm

NEW YORK, Sept. 30, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inve
benzinga.com
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89

Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises

Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down – Time to Sell?
defenseworld.net
Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down – Time to Sell?

Travere Therapeutics, Inc. (NASDAQ: TVTX - Get Free Report)'s stock price gapped down before the mar

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental G
gurufocus.com
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S.

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademar

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
businesswire.com
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S.

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the Unite
benzinga.com
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target

Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and m
benzinga.com
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Travere Therapeutics (NASDAQ:TVTX) wi
benzinga.com
Travere Therapeutics Appoints Bradley L. Campbell President, CEO, Effective Dec. 1, Succeeding Eric

Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Eric Dube, Ph.D., has made the difficu

Travere Therapeutics Announces Planned Chief Executive Officer Transition
businesswire.com
Travere Therapeutics Announces Planned Chief Executive Officer Transition

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that

Insider Selling: Travere Therapeutics (NASDAQ:TVTX) EVP Sells $538,909.74 in Stock
defenseworld.net
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) EVP Sells $538,909.74 in Stock

Travere Therapeutics, Inc. (NASDAQ: TVTX - Get Free Report) EVP Peter Heerma sold 8,282 shares of th

Travere Therapeutics (NASDAQ:TVTX) Insider Sells $2,337,750.00 in Stock
defenseworld.net
Travere Therapeutics (NASDAQ:TVTX) Insider Sells $2,337,750.00 in Stock

Travere Therapeutics, Inc. (NASDAQ: TVTX - Get Free Report) insider Elizabeth Reed sold 37,500 share

Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
businesswire.com
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company m

Bank of America Corp DE Invests $259.53 Million in Travere Therapeutics, Inc. $TVTX
defenseworld.net
Bank of America Corp DE Invests $259.53 Million in Travere Therapeutics, Inc. $TVTX

Bank of America Corp DE acquired a new stake in shares of Travere Therapeutics, Inc. (NASDAQ: TVTX)

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on Septem

Hsbc Holdings PLC Sells 176,242 Shares of Travere Therapeutics, Inc. $TVTX
defenseworld.net
Hsbc Holdings PLC Sells 176,242 Shares of Travere Therapeutics, Inc. $TVTX

Hsbc Holdings PLC cut its stake in shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) by 44.4% in t

Artia Global Partners LP Buys New Shares in Travere Therapeutics, Inc. $TVTX
defenseworld.net
Artia Global Partners LP Buys New Shares in Travere Therapeutics, Inc. $TVTX

Artia Global Partners LP purchased a new stake in Travere Therapeutics, Inc. (NASDAQ: TVTX) in the s

Travere Therapeutics: Valuation Suggests A Buy
seekingalpha.com
Travere Therapeutics: Valuation Suggests A Buy

Travere Therapeutics is rated Buy, with a DCF-based fair value of ~$81 per share, implying 27% upsid

Everest Medicines Reports 1H 2026 Results, Enters New Phase as Growth Accelerates and Innovation Gains Momentum
gurufocus.com
Everest Medicines Reports 1H 2026 Results, Enters New Phase as Growth Accelerates and Innovation Gai

HONG KONG, Aug 19, 2026 - (ACN Newswire) - Everest Medicines (01952.HK) announced its interim result

Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline
marketbeat.com
Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline

Travere Therapeutics NASDAQ: TVTX is pursuing growth through expanded use of FILSPARI in rare kidney

Bank of America Corp DE Trims Position in Travere Therapeutics, Inc. $TVTX
defenseworld.net
Bank of America Corp DE Trims Position in Travere Therapeutics, Inc. $TVTX

Bank of America Corp DE lessened its holdings in shares of Travere Therapeutics, Inc. (NASDAQ: TVTX)

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on August
benzinga.com
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $78

Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outper
benzinga.com
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $70

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and
benzinga.com
Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $75

Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and ra

Travere Therapeutics Q2 Earnings: Why I'm Downgrading To Hold (Again)
seekingalpha.com
Travere Therapeutics Q2 Earnings: Why I'm Downgrading To Hold (Again)

Travere Therapeutics is downgraded from Buy to Hold after a >130% rally, reflecting competitive risk

Empowered Funds LLC Increases Holdings in Travere Therapeutics, Inc. $TVTX
defenseworld.net
Empowered Funds LLC Increases Holdings in Travere Therapeutics, Inc. $TVTX

Empowered Funds LLC boosted its holdings in Travere Therapeutics, Inc. (NASDAQ: TVTX) by 2,719.8% in
benzinga.com
TD Cowen Maintains Buy on Travere Therapeutics, Raises Price Target to $75

TD Cowen analyst Tyler Van Buren maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and rais
benzinga.com
Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $85

Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and r
benzinga.com
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $68

Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outper

Wynn Resorts Posts Upbeat Q2 Earnings, Joins Bloomin' Brands, Shopify, Owens Corning And Other Big Stocks Moving Higher On Wednesday
benzinga.com
Wynn Resorts Posts Upbeat Q2 Earnings, Joins Bloomin' Brands, Shopify, Owens Corning And Other Big S

US stocks rise, Wynn Resorts beat earnings expectations, share price jumps 10.9%. Other companies re
benzinga.com
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $75

Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 43.0% to $1.43 during Wednesday&#

Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On
benzinga.com
Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On

Travere Therapeutics shares surged 13.44% after hours as strong revenue growth and FILSPARI sales ga

12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday'
benzinga.com
Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $62

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and
benzinga.com
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $65

Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises
benzinga.com
Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $61

Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and ra
benzinga.com
Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $60

Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outper
benzinga.com
Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $70

Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and r
benzinga.com
Wells Fargo Maintains Overweight on Travere Therapeutics, Raises Price Target to $65

Wells Fargo analyst Mohit Bansal maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight a
benzinga.com
Travere Therapeutics Announces Long-Term Results From Ongoing Phase 3 DUPLEX Study Open-Label Extens

Patients in the study who initiated and remained on FILSPARI maintained durable and deepened protein
benzinga.com
Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $62

Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and r
benzinga.com
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $55 Price Target

Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and m
benzinga.com
HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $67

HC Wainwright & Co. analyst Joseph Pantginis maintains Travere Therapeutics (NASDAQ:TVTX) wit
benzinga.com
Travere Therapeutics Enters Into Exclusive Licensing And Collaboration Agreement With Everest Medici

Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide dif
benzinga.com
Travere Therapeutics Receives Notice Of Allowance From U.S. Patent And Trademark Office For Patent T

Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that the United States Patent and Trademark
benzinga.com
Wells Fargo Maintains Overweight on Travere Therapeutics, Raises Price Target to $50

Wells Fargo analyst Mohit Bansal maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight a
benzinga.com
Travere Therapeutics Plans To Offer $400M Senior Convertible Notes Due 2032

Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced its intention to offer, subject to market a

Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings
benzinga.com
Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings

Travere Therapeutics (NASDAQ:TVTX) reported a profit in Q1, surpassing analyst estimates. Shares fel